Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Arcus Biosciences, Inc.
Duke University
University of Oklahoma
Poseida Therapeutics, Inc.
Werewolf Therapeutics, Inc.
University of California, Davis
City of Hope Medical Center
ImmunityBio, Inc.
Novartis
Bayer
Inhibrx Biosciences, Inc
Incyte Corporation
Bristol-Myers Squibb
EMD Serono
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
HiFiBiO Therapeutics
Ohio State University Comprehensive Cancer Center
University of Pittsburgh
Nanobiotix
Sichuan Baili Pharmaceutical Co., Ltd.
Vyriad, Inc.
Asher Biotherapeutics, Inc.
Exelixis
Jonsson Comprehensive Cancer Center
Oslo University Hospital
Merck Sharp & Dohme LLC
Checkpoint Therapeutics, Inc.
Nimbus Therapeutics
Dana-Farber Cancer Institute
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
RemeGen Co., Ltd.
ImaginAb, Inc.
Biomica Ltd.
NGM Biopharmaceuticals, Inc
AO GENERIUM
Instil Bio